VivoSeq
Psychiatry

Generalized Anxiety Disorder

72

Pipeline Programs↗

17

Active Trials↗

34

Companies Involved↗

Generalized Anxiety Disorder is a moderately active landscape with 72 programs across 34 companies. The most active players are Merck & Co., Novartis, Engrail Therapeutics INC. 14 therapies are approved with 29 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

22/100

Mech. Concentration

20/100

Completion Rate

86/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2E

Engrail Therapeutics INC

1 program

Phase 2S

Synendos Therapeutics AG

1 program

Phase 2COMPASS Pathways logo

COMPASS Pathways

1 program

Phase 2Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.

3 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

119

clinical trials

Completed85 · 71%
Terminated12 · 10%
Recruiting10 · 8%
Active, not recruiting5 · 4%
Unknown status3 · 3%
Not yet recruiting2 · 2%
Other2 · 2%

Clinical Trials

Trial Activity

119 trials

Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Recruiting·IIntra-Cellular Therapies, Inc.·Phase 2·NCT06701903·570 enrolled
Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder
Recruiting·—·Phase 2·NCT07330648·216 enrolled
Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study
Recruiting·QQueen's University·Phase 4·NCT06218030·10 enrolled
Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder
Recruiting·SSichuan Jishengtang Pharmaceutical Co., Ltd.·Phase 3·NCT05772104·495 enrolled
Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
Recruiting·QQueen's University·Phase 2·NCT06969170·50 enrolled
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Recruiting·AbbVie logoAbbVie·Phase 2·NCT06846320·315 enrolled
Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder
Recruiting·WWayne State University·Phase 3·NCT07123467·90 enrolled
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Recruiting·IIntra-Cellular Therapies, Inc.·Phase 2·NCT06480383·705 enrolled
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Generalized Anxiety Disorder
Recruiting·RReunion Neuroscience Inc·Phase 2·NCT07489651·64 enrolled
CORAL-2: Zuranolone in Anxiety Disorders
Recruiting·Biogen logoBiogen·Phase 3·NCT06200002·650 enrolled
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
Active, not recruiting·CCybin IRL Limited·Phase 2·NCT06051721·36 enrolled
Clinical Trial to Evaluate the Efficacy and Safety of the Aurora® Digital Medical Device in Adult Patients With Moderate to Severe Generalized Anxiety Disorder
Active, not recruiting·PPsicofarma, S.A. De C.V.·Phase 3·NCT07477990·162 enrolled
Elucidating Neural Mechanisms and Sex Differences in Response to Mindfulness Based Stress Reduction in Generalized Anxiety Disorder
Active, not recruiting·NNYU Langone Health·Preclinical·NCT05064813·240 enrolled
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage
Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06741228·214 enrolled
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40 Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Panorama
Active, not recruiting·DDefinium Therapeutics US, Inc.·Phase 3·NCT06809595·245 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)